Asia

Indian regulators suspend operations at CRO Axis Clinicals

Tuesday, June 28, 2011 02:30 PM

India’s Drug Controller General (DGCI) has suspended operations at Hyderabad, India-based CRO Axis Clinicals and is vetting all bioavailability and bioequivalence study centers in Andhra Pradesh state after investigations revealed irregularities in a trial conducted by Axis, reported PharmaTimes.

More... »

Shanghai Pharma's IPO to top $2.1 billion

Friday, May 13, 2011 11:44 AM

Shanghai Pharmaceuticals has priced its proposed initial public offering in Hong Kong, which will top $2.13 billion, according to Pharma Times.

More... »

Approved: Daiichi Sanyo’s edoxaban

Tuesday, April 26, 2011 01:28 PM

Japan-based Daiichi Sankyo has received marketing approval by the Japanese Ministry of Health, Labor and Welfare for its anticoagulant edoxaban, according to Pharma Times.  

More... »

SciClone acquires NovaMed Pharmaceuticals

Tuesday, April 19, 2011 12:20 PM

California-based SciClone Pharmaceuticals has acquired NovaMed Pharmaceuticals, a China-based specialty pharmaceutical company, according to Fierce Biotech. The acquisition brings more sales and marketing as well as regulatory and business capabilities.  The pharmaceutical assets in the regulatory approval stage add to SciClone’s growing and profitable China-focused specialty pharmaceutical business.

More... »

Singapore develops its first cancer drug

Thursday, March 17, 2011 01:27 PM

Singapore has developed its first cancer drug, SB-939, from two Singapore-based cancer institutes and a biotechnology company, S*BIO, according to Channel News Asia.   The Singapore National University Cancer Institute, the Cancer Institute of Singapore and S*BIO have collaborated for the phase I trials.

More... »

CRO QPS acquires Qualitix

Wednesday, March 9, 2011 01:28 PM

QPS, a global GLP/GCP-compliant CRO providing testing services for preclinical and clinical R&D, has acquired a majority interest of Qualitix Clinical Research. Qualitix, a spin-off of Taiwan-based biotech Genovate, is a CRO and site management organization (SMO) with offices in Taiwan and China. Genovate will retain a minority interest in Qualitix, which will be known as QPS-Qualitix Taiwan.

More... »

Eisai reports new data on Halaven

Tuesday, March 8, 2011 10:24 AM

Eisai, based in Japan, reported new data confirming its marine-derived drug Halaven improves overall survival in women with late-stage breast cancer. 

More... »

WuXi reports 2Q revenue growth after Charles River deal fails

Friday, August 6, 2010 08:45 AM

Shanghai-based WuXi PharmaTech will receive a breakup fee of $30 million from Charles River Laboratories International, whose previously announced purchase of Wuxi was terminated by mutual agreement due to Charles River shareholder opposition.

More... »

PPD Named Best CRO in Asia

Thursday, July 1, 2010 08:20 AM

PPD was named Best Contract Research Organization (CRO) in Asia at the World Vaccine Congress’ inaugural 2010 Vaccine Industry Excellence (ViE) Asia Awards held in Singapore.

More... »

Parexel Adds Two Locations in China

Thursday, May 27, 2010 09:11 AM

Parexel has opened two new offices in China, increasing its presence in the Asia-Pacific region to 17 locations, in order to meet growing demand for clinical development and regulatory consulting services from drug sponsors looking for more opportunities to include China in global drug development strategies.

More... »